ZyVersa Therapeutics Files 8-K: Material Agreement & Equity Sales
Ticker: ZVSA · Form: 8-K · Filed: Jun 25, 2025 · CIK: 1859007
| Field | Detail |
|---|---|
| Company | Zyversa Therapeutics, Inc. (ZVSA) |
| Form Type | 8-K |
| Filed Date | Jun 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-k
TL;DR
ZyVersa filed an 8-K detailing a material agreement and equity sales. Keep an eye on this.
AI Summary
ZyVersa Therapeutics, Inc. announced on June 24, 2025, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securities and other events. This filing was made on June 25, 2025, and pertains to the period ending June 24, 2025.
Why It Matters
This 8-K filing indicates significant corporate activity, including a material definitive agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing mentions unregistered sales of equity securities, which can sometimes indicate financing needs or dilution concerns.
Key Players & Entities
- ZyVersa Therapeutics, Inc. (company) — Registrant
- June 24, 2025 (date) — Date of earliest event reported
- June 25, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 001-41184 (identifier) — SEC File Number
- Larkspur Health Acquisition Corp. (company) — Former company name
FAQ
What is the nature of the Material Definitive Agreement mentioned in the filing?
The filing states that ZyVersa Therapeutics, Inc. entered into a Material Definitive Agreement on June 24, 2025, but the specific details of this agreement are not provided in the excerpt.
What type of equity securities were sold unregistered?
The filing mentions 'Unregistered Sales of Equity Securities' as an item of disclosure, but the specific type and details of these securities are not detailed in the provided text.
When was ZyVersa Therapeutics, Inc. formerly known as Larkspur Health Acquisition Corp.?
The company's name change from Larkspur Health Acquisition Corp. to ZyVersa Therapeutics, Inc. occurred on April 26, 2021.
What is ZyVersa Therapeutics, Inc.'s principal executive office address?
ZyVersa Therapeutics, Inc.'s principal executive offices are located at 2200 N. Commerce Parkway, Suite 208, Weston, Florida 33326.
What is the SIC code for ZyVersa Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for ZyVersa Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 25, 2025 regarding ZyVersa Therapeutics, Inc. (ZVSA).